TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.33
+0.43%Oct 15, 2026, 12:00 UTC
Protara Therapeutics, Inc. completed enrollment of 24 patients in the Phase 2b open-label dose-confirmation phase of its THRIVE-3 trial evaluating IV choline chloride in patients with intestinal failure dependent on parenteral support.
Source:Aug 11, 2026, 00:00 UTC
Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.
Jun 29, 2026, 00:00 UTC
Leonardo Viana Nicacio, M.D. resigned as Chief Medical Officer of Protara Therapeutics, Inc., effective June 26, 2026.